Fig. 3

The anti-tumor effect of tasquinimod operates during the first week of tumor development. BALB/c and C57Bl/6 mice were inoculated s.c. with 10⁵ 4 T1 and 10⁵ B16 tumor cells, respectively. Tasquinimod (25 mg/kg/day) was given in the drinking water during the indicated time points. Once palpable, tumors were frequently measured throughout the study and collected at day 14–15 post-inoculation. a, 4 T1 tumor growth curves (left) and tumor weights at day 14 post-inoculation (right) (ctrl, n = 7; tasq 0–7, n = 7; tasq 0–14, n = 6). b, B16 tumor growth curves (left) and tumor weights at day 15 post-inoculation (right) (ctrl, n = 6; tasq 0–7, n = 8; tasq 0–15, n = 10). c, Frequency of CD11b⁺, Ly6C^hi, Ly6G^hi and SiglecF⁺ cells gated from total viable CD45.2⁺ or CD11b⁺ CD45.2⁺ cells in 4 T1 tumors at day 14 post-inoculation. d, 4 T1 tumor growth curves (left) and tumor weights at day 15 post-inoculation (right) (ctrl, n = 6; tasq 0–15, n = 6; tasq 3–15, n = 6). Representative results of two independent experiments are shown for all experimental settings. n.s. = not significant, *P < 0.05, **P < 0.01, Mann–Whitney U-test